NCCN task force report: Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia

Medicine & Life Sciences

• Advisory Committees 100%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 98%
• Protein-Tyrosine Kinases 85%
• Imatinib Mesylate 35%
• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 30%
• Dasatinib 28%
• Therapeutics 15%
• Leukemia, Myeloid, Chronic Phase 14%
• Blast Crisis 14%
• Expert Testimony 10%
• Cytogenetics 10%
• Standard of Care 10%
• Disease Progression 8%
• Mutation 5%